Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’ Sotyktu at clearing skin and easing symptom severity in patients with plaque psoriasis.
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’ Sotyktu at clearing skin and easing symptom severity in patients with plaque psoriasis.